[195mPt]顺铂用于肺癌显像的初步研究
这项可行性研究评估了[195mPt]顺铂SPECT/CT在非小细胞肺癌(NSCLC)患者中的辐射安全性、生物分布与图像质量。6例患者放化疗第2或第3周接受100 MBq [195mPt]顺铂,未观察到2级以上不良事件;有效剂量为14.6 ± 1.5 mSv,有效半衰期为74.8小时,肝脏与肾脏摄取最高,肿瘤摄取值与血液相似(比值1.0 ± 0.05)。
要点
- 6例NSCLC患者注射100 MBq [195mPt]顺铂后未观察到2级以上不良事件。
- 平均有效剂量为14.6 ± 1.5 mSv,有效半衰期为74.8小时。
- 肝脏与肾脏摄取最高,肿瘤摄取与血液相似(比值1.0 ± 0.05)。
核心结论
- [195mPt]顺铂在注射100 MBq用于NSCLC患者显像时是安全的,平均有效剂量为14.6 ± 1.5 mSv。
- [195mPt]顺铂的图像质量适合SPECT显像与定量,肿瘤摄取与血液相似。
研究设计与样本
- 可行性研究,纳入6例非小细胞肺癌(NSCLC)患者,在其放化疗第2或第3周给予100 MBq [195mPt]顺铂。
- [195mPt]顺铂按GMP标准生产,于给药后1.5、48、120和168小时采集平面与SPECT/CT显像。
- 使用3DSlicer中的TotalSegmentator进行SPECT分割以评估生物分布与剂量学,通过单指数曲线拟合生成器官特异性时间-活性曲线,有效剂量与吸收剂量采用IDAC-Dose 2.1的S值获得。
- 毒性按CTCAE标准评估。
主要发现
- 6例NSCLC患者接受的[195mPt]顺铂活度为100.9 ± 3.3 MBq,放射性浓度为11.1 ± 4.9 MBq/mL。
- 未观察到2级以上不良事件。
- [195mPt]顺铂滞留时间长,有效半衰期为74.8小时。
- 肝脏与肾脏摄取最高,吸收剂量分别为48.6 ± 7.9 mGy和38.4 ± 7.3 mGy。
- 肿瘤摄取与血液相似,比值为1.0 ± 0.05。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Radiolabeled [195mPt]cisplatin has been developed as a tool to determine the biodistribution of cisplatin in vivo through SPECT imaging and possibly aid in patient-selection. This feasibility study aimed to evaluate the (radiation) safety, biodistribution, and image quality of [195mPt]cisplatin SPECT/CT in patients with non-small cell lung cancer (NSCLC). [195mPt]Cisplatin was produced under GMP standards. Six patients received 100 MBq [195mPt]cisplatin in their second or third week of chemoradiation therapy. Planar and SPECT/CT imaging were acquired at 1.5, 48, 120 and 168 h post-administration. Segmentation on SPECT for biodistribution and dosimetry was achieved using TotalSegmentator in 3DSlicer, and organ specific time-activity curves were generated through a mono-exponential curve fit. Effective and absorbed doses were obtained with S-values from IDAC-Dose 2.1. Toxicity was assessed using CTCAE criteria. RESULTS: Six NSCLC patients received 100.9 ± 3.3 MBq [195mPt]cisplatin at a radioactivity concentration of 11.1 ± 4.9 MBq/mL. No adverse events above grade 2 were observed. [195mPt]Cisplatin had a long retention time with an effective half-life of 74.8 h. Uptake was highest in the liver and kidneys, which also resulted in the highest absorbed dose at 48.6 ± 7.9 mGy and 38.4 ± 7.3 mGy, respectively. Tumor uptake was similar to blood, with a ratio of 1.0 ± 0.05. CONCLUSION: [195mPt]Cisplatin is safe to use for imaging in patients with NSCLC when injecting 100 MBq, reaching a mean effective dose of 14.6 ± 1.5 mSv. The image quality of [195mPt]cisplatin was suitable for SPECT imaging and quantification. Tumor uptake was similar to blood. TRIAL REGISTRATION: CCMO, NL74272.031.21. Registered 28 January 2022, https://www.onderzoekmetmensen.nl/nl/trial/55147 .
引用
- Hoogenkamp DS, de Wit-van der Veen BJ, Hendriksen J, et al. [195mPt]Cisplatin for lung cancer imaging: a pilot study. EJNMMI Res. 2025. PMID: 40668468. doi:10.1186/s13550-025-01281-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。